Pancreatic Cancer Research

ResearcherChinese Academy of SciencesActive in the last 2 years

Yinmo Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6202-6535; OpenAlex author ID A5101120893, A5101430386, A5138050651. Sources: OpenAlex.

Their work

Papers
37 (first author 0, last author 24)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: 6 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 5 papers · 2026: 4 papers

Papers 37

  1. Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis. Last author DOI 10.1002/advs.75216↗
  2. Exosomal miR-4644 Targets SPRY3 to Promote Proliferation and Invasion of Pancreatic Cancer. Last author DOI 10.1002/cam4.72000↗
  3. A deep learning pathomic signature predicts survival and recurrence in pancreatic ductal adenocarcinoma independent of CA19-9. Co-author DOI 10.1016/j.canlet.2026.218452↗
  4. The Acidic Exosomal miR-1246/WASF3 Axis Regulates Hepatic Stellate Cell Activation and Stiff ECM Remodeling to Promote Pancreatic Ductal Adenocarcinoma Liver M… Last author DOI 10.7150/ijbs.132772↗
  5. Tumor-derived exosomes: Unravelling the pathogenesis of pancreatic cancer with liver metastases and exploring the potential for clinical translation. Last author DOI 10.1016/j.canlet.2024.217403↗
  6. SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113713↗
  7. Organoid in droplet: Production of uniform pancreatic cancer organoids from single cells. Co-author DOI 10.1016/j.mtbio.2025.101765↗
  8. Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer. Co-author DOI 10.1186/s12967-025-06152-8↗
  9. Current status and future prospects of cancer-derived immunoglobulins in pancreatic cancer. Co-author DOI 10.7150/jca.109497↗
  10. SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression. Co-author DOI 10.1016/j.canlet.2024.217109↗
  11. Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis. Last author DOI 10.3389/fonc.2024.1327280↗
  12. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis. Last author DOI 10.1007/s10238-023-01112-2↗
  13. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. Last author DOI 10.1016/j.canlet.2023.216421↗
  14. [Current surgical concepts and future perspectives in the treatment of pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20221021-00453↗
  15. [Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer]. Last author DOI 10.3760/cma.j.cn112139-20230510-00199↗
  16. Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1. Last author DOI 10.1097/cm9.0000000000002154↗
  17. Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study. Co-author DOI 10.1177/10732748221084853↗
  18. The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"? Co-author DOI 10.21037/hbsn-22-146↗
  19. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  20. Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis. Last author DOI 10.21037/atm-20-2194↗
  21. Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practic… Last author DOI 10.21037/hbsn-20-383↗
  22. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center anal… Last author DOI 10.21147/j.issn.1000-9604.2021.04.03↗
  23. [The comparison of prognosis factors after radical resection for pancreatic ductal adenocarcinoma between China Pancreas Data Center and SEER database]. Last author DOI 10.3760/cma.j.cn112139-20210507-00202↗
  24. Unfolded protein response activated by endoplasmic reticulum stress in pancreatic cancer: potential therapeutical target. Co-author DOI 10.52586/5061↗
  25. Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China. Last author PMID 34249444↗
  26. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Last author DOI 10.1016/j.canlet.2020.06.009↗
  27. Current status and future prospect of surgical treatment for pancreatic cancer. Co-author DOI 10.21037/hbsn.2019.12.04↗
  28. LncRNA H19-Derived miR-675-3p Promotes Epithelial-Mesenchymal Transition and Stemness in Human Pancreatic Cancer Cells by targeting the STAT3 Pathway. Last author DOI 10.7150/jca.44833↗
  29. BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Last author DOI 10.1016/j.canlet.2019.02.031↗
  30. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagi… Last author DOI 10.1002/ijc.31211↗
  31. Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Last author DOI 10.3892/or.2018.6178↗
  32. Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. Last author DOI 10.7150/jca.21347↗
  33. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Last author DOI 10.1016/j.canlet.2017.05.006↗
  34. [Evaluation of American Joint Commission on Cancer(8th edition) and Japanese Pancreas Society(7th edition)changes for T and N staging in patients with pancreat… Co-author DOI 10.3760/cma.j.issn.0529-5815.2017.01.006↗
  35. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. Last author DOI 10.1080/15384047.2016.1219814↗
  36. Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem-Like Cells. Last author DOI 10.7150/jca.13305↗
  37. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Last author DOI 10.1007/s10620-013-2673-2↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tian · 18 shared papers, 2016–2026 · strength 3.31
  2. Yongsu Ma · 14 shared papers, 2018–2026 · strength 2.82
  3. Xiaodong Tian · 12 shared papers, 2013–2025 · strength 1.61
  4. Zhengkui Zhang · 11 shared papers, 2016–2022 · strength 1.09
  5. Xiangyu Chu · 3 shared papers, 2025–2026 · strength 0.86
  6. Yiran Chen · 4 shared papers, 2021–2025 · strength 0.78
  7. Feng Wang · 8 shared papers, 2016–2022 · strength 0.71
  8. Ling Ma · 8 shared papers, 2016–2022 · strength 0.70
  9. Weikang Liu · 4 shared papers, 2021–2023 · strength 0.61
  10. Huahu Guo · 6 shared papers, 2017–2021 · strength 0.59
  11. Dongqi Li · 2 shared papers, 2026 · strength 0.58
  12. Xiaodong Tian · 2 shared papers, 2026 · strength 0.57
  13. Marko Kornmann · 7 shared papers, 2016–2020 · strength 0.55
  14. Yingjin Wang · 2 shared papers, 2023–2026 · strength 0.46
  15. Hao Hu · 3 shared papers, 2021 · strength 0.44
  16. Long Di · 2 shared papers, 2023 · strength 0.38
  17. Chong Du · 5 shared papers, 2016–2019 · strength 0.37
  18. Kai Chen · 2 shared papers, 2020–2023 · strength 0.32
  19. Dongqi Li · 1 shared paper, 2025 · strength 0.28
  20. Mingzhe Li · 2 shared papers, 2020–2022 · strength 0.28
  21. Xu Zhang · 1 shared paper, 2023 · strength 0.26
  22. Jianhua Qin · 1 shared paper, 2025 · strength 0.26
  23. Xin Wang · 1 shared paper, 2025 · strength 0.26
  24. Shan-Wen Chen · 1 shared paper, 2025 · strength 0.26
  25. Haitao Liu · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.